Management of obstetric antiphospholipid syndrome. - Wikidata - awgldk - TriplyDB

Management of obstetric antiphospholipid syndrome.

Management of obstetric antiphospholipid syndrome.

http://www.wikidata.org/entity/Q37959314

about

Understanding and Managing Pregnancy in Patients with Lupus Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management.Guidelines for the treatment of antiphospholipid syndrome.Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy.A importância de reconhecer a síndrome antifosfolípide na medicina vascular.

P2860

Q26798179-0A926DF4-C73B-4D9A-BDCB-2499445E3543 Q34476952-0BBF5B21-0EB5-473F-B392-1A5AD2B6E0E2 Q34821893-ED96EAAC-B808-445D-9D89-57B3EE816ADB Q38175887-9E0D5C08-EB91-4F0F-87F1-A8AAD468C9B5 Q38876334-1DFCA0A1-674B-443B-9123-22BB89BAC37C Q50079687-60D08BF2-CF94-44A0-8366-A24E129F5544 Q55279180-962DEBA4-17E4-4057-9262-FA59F3C2EF67

P2860

Management of obstetric antiphospholipid syndrome.

http://www.wikidata.org/entity/Q37959314

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of obstetric antiphospholipid syndrome.

@en

Management of obstetric antiphospholipid syndrome.

@nl

type

label

Management of obstetric antiphospholipid syndrome.

@en

Management of obstetric antiphospholipid syndrome.

@nl

prefLabel

Management of obstetric antiphospholipid syndrome.

@en

Management of obstetric antiphospholipid syndrome.

@nl

P1433

Q37959314-8798A519-8DBF-484C-9B05-CCD455F401C1

P1476

Q37959314-CE244E39-2EF3-4582-AA4B-60493E9C83E0

P2093

Q37959314-3D3E4598-48D6-42A6-BB70-FE0C1E45AFC6

Q37959314-59C79D5D-5477-4FC6-8CEF-F7D8E5BC61A6

Q37959314-604731CF-A2D2-4895-9D08-4D528008BDBB

Q37959314-619826EE-47B4-4D1D-AEDC-4E6B9B1EE29F

Q37959314-B31DA5FC-59A1-4181-A060-39C09D995928

P2860

Q37959314-124A9DC6-607F-4221-BDF4-C20D8BBD0AF0

Q37959314-18299BFA-FA16-4853-9624-56DA8CC68C24

Q37959314-1EA69ED4-EB17-4782-AEF2-3EF86166BD9F

Q37959314-20A31BF9-46CC-46FB-A33B-2A1C8CF6AC71

Q37959314-20FF783A-0284-4D8F-BB79-6E6A0626FD62

Q37959314-2839F0E8-E0EE-4F4A-B173-D7834D7797D2

Q37959314-3751CAAD-BD3F-4E3D-A6B8-80D81840CC3F

Q37959314-3A01D1A1-C9C2-4618-B203-4E0B328B59AD

Q37959314-3A390386-22F2-4CBC-951D-0CF321C87ACD

Q37959314-3B8764AE-B4EB-44A0-9398-7F6E2C55A8E9

P2888

Q37959314-125E6E7B-C476-41F5-AB87-086FE1696521

P304

Q37959314-A0D62F97-6648-4AF7-BC52-4DED6E6BD5D8

P31

Q37959314-8C6A7B5C-60F2-433C-868B-E8983CB2CBFC

P356

Q37959314-2C5A74AF-7D9C-40B5-9B8F-782072BCA650

P433

Q37959314-989FF82E-B4E6-4921-8B49-7799DF2EF668

P478

Q37959314-1F0BFA1E-48D5-4C0E-B970-B9B4133D6BF7

P50

Q37959314-787C6A10-E3D9-4F96-9ADD-A6DA72314A51

P577

Q37959314-375EF81D-7EEC-4B1C-A233-674644C13F02

P698

Q37959314-2F5930C1-0FF9-48D9-B615-F1B68109ABE3

P356

S11926-011-0218-2

P1433

Current Rheumatology Reports

P1476

Management of obstetric antiphospholipid syndrome.

@en

P2093

Camila Souto Oliveira

http://www.w3.org/2001/XMLSchema#string

Flavia Cunha dos Santos

http://www.w3.org/2001/XMLSchema#string

Guilherme Ribeiro Ramires de Jesus

http://www.w3.org/2001/XMLSchema#string

Nilson Ramires de Jesus

http://www.w3.org/2001/XMLSchema#string

Wallace Mendes-Silva

http://www.w3.org/2001/XMLSchema#string

P2860

Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin

Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome

Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment

Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies

Management of antiphospholipid syndrome in pregnancy

Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin

Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin

Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.

Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.

P2888

s11926-011-0218-2

P304

79-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-011-0218-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22105547

http://www.w3.org/2001/XMLSchema#string